Suppr超能文献

印度甲状腺功能亢进症患者的骨矿物质密度趋势——抗甲状腺治疗的影响

Bone mineral density trends in Indian patients with hyperthyroidism--effect of antithyroid therapy.

作者信息

Dhanwal Dinesh Kumar, Gupta Nandita

机构信息

Maulana Azad Medical College, New Delhi.

出版信息

J Assoc Physicians India. 2011 Sep;59:561-2, 567.

Abstract

BACKGROUND

Hyperthyroidism is associated with bone loss, which is reversible after treatment. The extent of reversibility of loss of bone mass density (BMD) in hyperthyroid patients after treatment especially at forearm is not clear. Therefore, the present study was conducted to assess degree of reversibility in bone mineral density following one-year medical treatment in Indian patients with hyperthyroidism.

METHODS

A total of 30 consecutive patients with hyperthyroidism were included in this one year study at All India Institute of Medical Sciences, New Delhi, India. All the patients were assessed for parameters of bone mineral homeostasis such as calcium, phosphorous, alkaline phosphatase, 25-hydroxy vitamin D [25 (OH) D], parathyroid hormone (PTH) at the time of diagnosis and after one year medical treatment. Bone mineral density was measured using Hologic DXA scan at hip, spine and forearm. All the patients received medical therapy with carbimazole. The parameters of bone homeostasis and bone mineral density at base line and after one year medical treatment was compared.

RESULTS

All patients attained euthyroid status after eight weeks of carbimazole therapy. Parameters of bone homeostasis such as calcium, phosphorous, 25 (OH) D and PTH did not show any significant change from base line. Bone mineral density expressed as bone mineral content in gm/cm2 at left hip neck, trochanteric and intertrochanteric region was significantly higher after carbimazole therapy (745.2 +/- 127.6 gm/cm2 vs. 688.2 +/- 123.5 gm/cm2; p = 0.02, 573.4 +/- 109.9 gm/cm2 vs. 641.0 +/- 138.0 gm/cm2, p = 0.005 and 1008.6 +/- 185.5 gm/cm2 vs. 938.0 +/- 145.3 gm/cm2 p = 0.0131 respectively). Bone mineral density at lumbar spine expressed as either T and Z score was significantly higher after treatment (10 months of euthyroid state) (-0.6 +/- 1.3 vs. -1.7 +/- 1.2, p = 0.013 and -0.4 +/- 1.2 vs. -1.4 +/- 1.2, p = 0.012 respectively). However Bone mineral measures as T and Z score at left forearm decreased significantly after one year of medical therapy.

CONCLUSION

In Indian patients with hyperthyroidism, the pattern of recovery of bone loss after one year of antithyroid therapy suggests early recovery at hip and lumbar spine and deterioration at forearm.

摘要

背景

甲状腺功能亢进与骨质流失有关,治疗后骨质流失是可逆的。甲状腺功能亢进患者治疗后骨密度(BMD)的可逆程度,尤其是在前臂的情况尚不清楚。因此,本研究旨在评估印度甲状腺功能亢进患者接受一年药物治疗后骨矿物质密度的可逆程度。

方法

在印度新德里全印度医学科学研究所进行的这项为期一年的研究中,共纳入了30例连续的甲状腺功能亢进患者。在诊断时和接受一年药物治疗后,对所有患者进行骨矿物质稳态参数评估,如钙、磷、碱性磷酸酶、25-羟基维生素D [25(OH)D]、甲状旁腺激素(PTH)。使用Hologic DXA扫描仪测量髋部、脊柱和前臂的骨密度。所有患者均接受卡比马唑药物治疗。比较基线时和一年药物治疗后的骨稳态参数和骨密度。

结果

卡比马唑治疗8周后,所有患者均达到甲状腺功能正常状态。骨稳态参数如钙、磷、25(OH)D和PTH与基线相比无显著变化。卡比马唑治疗后,左髋部颈部、大转子和转子间区域以克/平方厘米表示的骨矿物质含量的骨密度显著更高(分别为745.2±127.6克/平方厘米对688.2±123.5克/平方厘米;p = 0.02,573.4±109.9克/平方厘米对641.0±138.0克/平方厘米,p = 0.005,1008.6±185.5克/平方厘米对938.0±145.3克/平方厘米,p = 0.0131)。治疗后(甲状腺功能正常状态10个月),腰椎的骨密度以T值和Z值表示均显著更高(分别为-0.6±1.3对-1.7±1.2,p = 0.013;-0.4±1.2对-1.4±1.2,p = 0.012)。然而,药物治疗一年后,左前臂以T值和Z值表示的骨矿物质测量值显著下降。

结论

在印度甲状腺功能亢进患者中,抗甲状腺治疗一年后骨质流失恢复的模式表明,髋部和腰椎早期恢复,而前臂则恶化。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验